Pfizer punts Seagen ADC, further muddying value of the $43B buyout

negativeNegative

AI Analysis

Summary

Pfizer has agreed to a co-development deal for a Seagen ADC following clinical failures of late-stage Seagen assets and discontinuation of another investigational therapy, further complicating the value proposition of Pfizer's $43 billion acquisition of Seagen.

Outcome Details

Late-stage failure for Seagen asset and discontinuation of another investigational therapy

Importance:7/10

Sentiment:

-0.80

SeagenADCclinical_failureacquisitiondrug_discontinuation

Related Companies

$PFE $PFE

Read the original article

Published by BioSpace on September 4, 2026 12:55 PM

Read Original